{"id":107504,"date":"2023-08-18T17:44:57","date_gmt":"2023-08-18T12:14:57","guid":{"rendered":"https:\/\/tradebrains.in\/features\/?p=107504"},"modified":"2023-08-18T17:45:04","modified_gmt":"2023-08-18T12:15:04","slug":"acquisition-lupin-acquires-2-brands-for-anti-diabetic-portfolio-from-boehringer-ingelheim","status":"publish","type":"post","link":"https:\/\/tradebrains.in\/features\/acquisition-lupin-acquires-2-brands-for-anti-diabetic-portfolio-from-boehringer-ingelheim\/","title":{"rendered":"Acquisition: Lupin Acquires 2 Brands for Anti Diabetic Portfolio From Boehringer Ingelheim"},"content":{"rendered":"<div class=\"trade-content_2\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-2948063943\"><p><a href=\"https:\/\/tradebrains.in\/get\/telegram\/\"><img decoding=\"async\" class=\"alignnone wp-image-101992\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/telegram-channel-300x119.png\" alt=\"\" width=\"148\" height=\"59\" \/><\/a> <a href=\"https:\/\/news.google.com\/publications\/CAAqBwgKMN3Epgswxc--Aw?hl=en-IN&amp;gl=IN&amp;ceid=IN%3Aen\"><img decoding=\"async\" class=\"alignnone wp-image-123430\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png\" alt=\"follow-on-google-news\" width=\"222\" height=\"61\" srcset=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png 300w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-150x41.png 150w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news.png 468w\" sizes=\"(max-width: 222px) 100vw, 222px\" \/><\/a><\/p>\n<\/div><p>Lupin is a pharmaceutical company, develops and sells a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) in India and abroad. <\/p><div class=\"trade-content_7\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-1134392848\"><!-- Composite Start --> \r\n <div id=\"M923760ScriptRootC1549812\"> \r\n <\/div> \r\n <script src=\"https:\/\/jsc.mgid.com\/t\/r\/tradebrains.in.1549812.js\" async> \r\n <\/script> \r\n <!-- Composite End --><\/div><p>The Mumbai-based drug maker said it has acquired Ondero and Ondero Met, including the trademark rights associated with these brands. The company said it has acquired two diabetes brands from Boehringer Ingelheim for an undisclosed amount.<\/p><p><strong><a href=\"https:\/\/portal.tradebrains.in\/stock\/LUPIN\/consolidated\" target=\"_blank\" rel=\"noreferrer noopener\">Lupin<\/a><\/strong> has been marketing the two brands since 2015 in the Indian market as part of a co-marketing agreement with Boehringer Ingelheim India. <\/p><p>In India, an estimated 77 million people above the age of 18 years have Type-2 Diabetes, while nearly 25 million are pre-diabetic, at higher risk of developing diabetes in the future. Ondero (Linagliptin) and Ondero Met (Linagliptin + Metformin) are the gold standard in diabetes management, Lupin stated.<\/p><div class=\"trade-content_5\" id=\"trade-1972275124\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_2_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"7925020301\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><p>Lupin Managing Director Nilesh Gupta said in a statement. Lupin MD Nilesh Gupta stated the action will further push them toward further consolidation of portfolio and strengthen their market leadership position in the antidiabetic segment by offering a wider spectrum of products and superior treatment.<\/p><p>Lupin India Regional Formulations President added to it, stating the acquisition represents their steadfast commitment to improve lives that are affected by the burden of a disease like diabetes and help patients navigate through the challenges that come with it.<\/p><div class=\"trade-after-content\" id=\"trade-728928939\"><div id=\"taboola-below-article-thumbnails\"><\/div>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({\r\n    mode: 'alternating-thumbnails-a',\r\n    container: 'taboola-below-article-thumbnails',\r\n    placement: 'Below Article Thumbnails',\r\n    target_type: 'mix'\r\n  });\r\n<\/script>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({flush: true});\r\n<\/script><\/div>","protected":false},"excerpt":{"rendered":"<p>Lupin is a pharmaceutical company, develops and sells a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) in India and abroad. The Mumbai-based drug maker said it has acquired Ondero and Ondero Met, including the trademark rights associated with these brands. The company said it has acquired two diabetes brands [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":21142,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[1697,31],"tags":[],"class_list":["post-107504","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-economy","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.5 (Yoast SEO v25.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Acquisition: Lupin Acquires 2 Brands for Anti Diabetic Portfolio From Boehringer Ingelheim - Trade Brains Features<\/title>\n<meta name=\"description\" content=\"Lupin is a pharmaceutical company, develops and sells a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) in India and abroad.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tradebrains.in\/features\/acquisition-lupin-acquires-2-brands-for-anti-diabetic-portfolio-from-boehringer-ingelheim\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Acquisition: Lupin Acquires 2 Brands for Anti Diabetic Portfolio From Boehringer Ingelheim\" \/>\n<meta property=\"og:description\" content=\"Lupin is a pharmaceutical company, develops and sells a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) in India and abroad.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tradebrains.in\/features\/acquisition-lupin-acquires-2-brands-for-anti-diabetic-portfolio-from-boehringer-ingelheim\/\" \/>\n<meta property=\"og:site_name\" content=\"Trade Brains Features\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TradeBrainsOfficial\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-18T12:14:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-18T12:15:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/Lupin-Cover-Image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"854\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Trade Brains\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:site\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Trade Brains\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/tradebrains.in\/features\/acquisition-lupin-acquires-2-brands-for-anti-diabetic-portfolio-from-boehringer-ingelheim\/\",\"url\":\"https:\/\/tradebrains.in\/features\/acquisition-lupin-acquires-2-brands-for-anti-diabetic-portfolio-from-boehringer-ingelheim\/\",\"name\":\"Acquisition: Lupin Acquires 2 Brands for Anti Diabetic Portfolio From Boehringer Ingelheim - Trade Brains Features\",\"isPartOf\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/tradebrains.in\/features\/acquisition-lupin-acquires-2-brands-for-anti-diabetic-portfolio-from-boehringer-ingelheim\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/tradebrains.in\/features\/acquisition-lupin-acquires-2-brands-for-anti-diabetic-portfolio-from-boehringer-ingelheim\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/Lupin-Cover-Image.jpg\",\"datePublished\":\"2023-08-18T12:14:57+00:00\",\"dateModified\":\"2023-08-18T12:15:04+00:00\",\"author\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\"},\"description\":\"Lupin is a pharmaceutical company, develops and sells a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) in India and abroad.\",\"breadcrumb\":{\"@id\":\"https:\/\/tradebrains.in\/features\/acquisition-lupin-acquires-2-brands-for-anti-diabetic-portfolio-from-boehringer-ingelheim\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/tradebrains.in\/features\/acquisition-lupin-acquires-2-brands-for-anti-diabetic-portfolio-from-boehringer-ingelheim\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/acquisition-lupin-acquires-2-brands-for-anti-diabetic-portfolio-from-boehringer-ingelheim\/#primaryimage\",\"url\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/Lupin-Cover-Image.jpg\",\"contentUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/Lupin-Cover-Image.jpg\",\"width\":1280,\"height\":854},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/tradebrains.in\/features\/acquisition-lupin-acquires-2-brands-for-anti-diabetic-portfolio-from-boehringer-ingelheim\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/tradebrains.in\/features\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Acquisition: Lupin Acquires 2 Brands for Anti Diabetic Portfolio From Boehringer Ingelheim\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/tradebrains.in\/features\/#website\",\"url\":\"https:\/\/tradebrains.in\/features\/\",\"name\":\"Trade Brains\",\"description\":\"Stock Market NSE\/BSE Latest News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/tradebrains.in\/features\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\",\"name\":\"Trade Brains\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"caption\":\"Trade Brains\"},\"sameAs\":[\"http:\/\/tradebrains.in\/\"],\"url\":\"https:\/\/tradebrains.in\/features\/author\/trade-brains\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Acquisition: Lupin Acquires 2 Brands for Anti Diabetic Portfolio From Boehringer Ingelheim - Trade Brains Features","description":"Lupin is a pharmaceutical company, develops and sells a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) in India and abroad.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tradebrains.in\/features\/acquisition-lupin-acquires-2-brands-for-anti-diabetic-portfolio-from-boehringer-ingelheim\/","og_locale":"en_US","og_type":"article","og_title":"Acquisition: Lupin Acquires 2 Brands for Anti Diabetic Portfolio From Boehringer Ingelheim","og_description":"Lupin is a pharmaceutical company, develops and sells a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) in India and abroad.","og_url":"https:\/\/tradebrains.in\/features\/acquisition-lupin-acquires-2-brands-for-anti-diabetic-portfolio-from-boehringer-ingelheim\/","og_site_name":"Trade Brains Features","article_publisher":"https:\/\/www.facebook.com\/TradeBrainsOfficial\/","article_published_time":"2023-08-18T12:14:57+00:00","article_modified_time":"2023-08-18T12:15:04+00:00","og_image":[{"width":1280,"height":854,"url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/Lupin-Cover-Image.jpg","type":"image\/jpeg"}],"author":"Trade Brains","twitter_card":"summary_large_image","twitter_creator":"@TradeBrainsGrp","twitter_site":"@TradeBrainsGrp","twitter_misc":{"Written by":"Trade Brains","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/tradebrains.in\/features\/acquisition-lupin-acquires-2-brands-for-anti-diabetic-portfolio-from-boehringer-ingelheim\/","url":"https:\/\/tradebrains.in\/features\/acquisition-lupin-acquires-2-brands-for-anti-diabetic-portfolio-from-boehringer-ingelheim\/","name":"Acquisition: Lupin Acquires 2 Brands for Anti Diabetic Portfolio From Boehringer Ingelheim - Trade Brains Features","isPartOf":{"@id":"https:\/\/tradebrains.in\/features\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tradebrains.in\/features\/acquisition-lupin-acquires-2-brands-for-anti-diabetic-portfolio-from-boehringer-ingelheim\/#primaryimage"},"image":{"@id":"https:\/\/tradebrains.in\/features\/acquisition-lupin-acquires-2-brands-for-anti-diabetic-portfolio-from-boehringer-ingelheim\/#primaryimage"},"thumbnailUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/Lupin-Cover-Image.jpg","datePublished":"2023-08-18T12:14:57+00:00","dateModified":"2023-08-18T12:15:04+00:00","author":{"@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666"},"description":"Lupin is a pharmaceutical company, develops and sells a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) in India and abroad.","breadcrumb":{"@id":"https:\/\/tradebrains.in\/features\/acquisition-lupin-acquires-2-brands-for-anti-diabetic-portfolio-from-boehringer-ingelheim\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tradebrains.in\/features\/acquisition-lupin-acquires-2-brands-for-anti-diabetic-portfolio-from-boehringer-ingelheim\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/acquisition-lupin-acquires-2-brands-for-anti-diabetic-portfolio-from-boehringer-ingelheim\/#primaryimage","url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/Lupin-Cover-Image.jpg","contentUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/Lupin-Cover-Image.jpg","width":1280,"height":854},{"@type":"BreadcrumbList","@id":"https:\/\/tradebrains.in\/features\/acquisition-lupin-acquires-2-brands-for-anti-diabetic-portfolio-from-boehringer-ingelheim\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tradebrains.in\/features\/"},{"@type":"ListItem","position":2,"name":"Acquisition: Lupin Acquires 2 Brands for Anti Diabetic Portfolio From Boehringer Ingelheim"}]},{"@type":"WebSite","@id":"https:\/\/tradebrains.in\/features\/#website","url":"https:\/\/tradebrains.in\/features\/","name":"Trade Brains","description":"Stock Market NSE\/BSE Latest News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tradebrains.in\/features\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666","name":"Trade Brains","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","caption":"Trade Brains"},"sameAs":["http:\/\/tradebrains.in\/"],"url":"https:\/\/tradebrains.in\/features\/author\/trade-brains\/"}]}},"_links":{"self":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/107504","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/comments?post=107504"}],"version-history":[{"count":2,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/107504\/revisions"}],"predecessor-version":[{"id":107509,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/107504\/revisions\/107509"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media\/21142"}],"wp:attachment":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media?parent=107504"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/categories?post=107504"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/tags?post=107504"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}